dihydroergotamine has been researched along with transforming growth factor beta in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, L; Cheng, ZY; Dong, M; Jiang, R; Jiang, XX; Jin, WZ; Wang, Q; Xie, W; Yan, CL; Ye, RC; Yuan, SL; Zhang, HL; Zhang, Z; Zheng, KX; Zhou, HQ | 1 |
1 other study(ies) available for dihydroergotamine and transforming growth factor beta
| Article | Year |
|---|---|
Dihydroergotamine ameliorates liver fibrosis by targeting transforming growth factor β type II receptor.
Topics: Animals; Dihydroergotamine; Fibrosis; Liver Cirrhosis; Mice; Molecular Docking Simulation; Receptor, Transforming Growth Factor-beta Type II; Receptors, Transforming Growth Factor beta; Transforming Growth Factor beta; Transforming Growth Factor beta1 | 2023 |